Toth Financial Advisory Corp buys $1,499,311 stake in Amgen (AMGN)

Amgen (AMGN) : Toth Financial Advisory Corp scooped up 1,882 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 13, 2016. The investment management firm now holds a total of 9,126 shares of Amgen which is valued at $1,499,311.Amgen makes up approximately 0.45% of Toth Financial Advisory Corp’s portfolio.

Other Hedge Funds, Including , Alta Capital Management reduced its stake in AMGN by selling 3 shares or 0.09% in the most recent quarter. The Hedge Fund company now holds 3,464 shares of AMGN which is valued at $569,101. Amgen makes up approx 0.04% of Alta Capital Management’s portfolio.Nisa Investment Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 6,774 additional shares and now holds a total of 308,415 shares of Amgen which is valued at $50,678,753. Amgen makes up approx 0.67% of Nisa Investment Advisors’s portfolio.Eagle Asset Management Inc reduced its stake in AMGN by selling 1,175 shares or 4.05% in the most recent quarter. The Hedge Fund company now holds 27,860 shares of AMGN which is valued at $4,577,955. Amgen makes up approx 0.03% of Eagle Asset Management Inc’s portfolio. Lvm Capital Management Ltdmi sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 69,845 shares of AMGN which is valued $11,680,878.

Amgen closed down -3.99 points or -2.37% at $164.32 with 27,61,896 shares getting traded on Tuesday. Post opening the session at $167.82, the shares hit an intraday low of $163.51 and an intraday high of $167.82 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.